Literature DB >> 7488812

Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children.

J Ksiazek1, T Wyszyńska.   

Abstract

A total of 184 children aged, 13 months to 11 years, suffering from their first attack of steroid-responsive nephrotic syndrome were included in a randomized study. They were treated according to three treatment protocols. All children received 1-2 mg of prednisone/kg body weight/day (up to 80 mg daily) for 4 weeks, and thereafter 1 mg/kg body weight/48 h for the next 4 weeks. Treatment was discontinued at this point in 44 children (protocol A); in 68 (protocol B) the dose was reduced by 25% each week, tapering off to 0 at the end of the third month, while in 72 children (protocol C), after the first 2 months of initial treatment the dose was reduced by 25% each month and tapered off to 0 by the end of the sixth month. All patients completed a 2-year follow-up period after withdrawal of prednisone. Treatment results were expressed as: percentage of children relapse-free within the first 6 months and 2 years after withdrawal of treatment, and average number of relapses per patient per year. The best results were obtained in children who had been treated for 6 months; 65.3% of them remained relapse-free within the first 6 months and 50% over the entire 2-year follow-up period; the number of relapses per patient per year in this group was 0.49. The respective values for children treated 2 and 3 months were: 36.4% and 32.4% for the 6-month period; 27.3% and 20.6% for the 2-year period; the numbers of relapses per patient per year were 0.79 and 0.77, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488812     DOI: 10.1111/j.1651-2227.1995.tb13787.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  24 in total

1.  Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial.

Authors:  Vaishnavi Raman; Sriram Krishnamurthy; K T Harichandrakumar
Journal:  Pediatr Nephrol       Date:  2016-01-12       Impact factor: 3.714

2.  Treatment of the first episode of nephrotic syndrome in children.

Authors:  Pavel Geier; Roman Jurencák; Jana Zapletalová
Journal:  Pediatr Nephrol       Date:  2006-08-11       Impact factor: 3.714

Review 3.  Corticosteroid therapy for nephrotic syndrome in children.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Narelle S Willis; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-03-18

4.  Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference?

Authors:  Sermin A Saadeh; Rossana Baracco; Amrish Jain; Gaurav Kapur; Tej K Mattoo; Rudolph P Valentini
Journal:  Pediatr Nephrol       Date:  2011-07-16       Impact factor: 3.714

5.  Should we stop dosing steroids per body surface area for nephrotics?

Authors:  Guido Filler; Lisa A Robinson
Journal:  Pediatr Nephrol       Date:  2015-12-28       Impact factor: 3.714

6.  Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome.

Authors:  Nynke Teeninga; Joana E Kist-van Holthe; Nienske van Rijswijk; Nienke I de Mos; Wim C J Hop; Jack F M Wetzels; Albert J van der Heijden; Jeroen Nauta
Journal:  J Am Soc Nephrol       Date:  2013-01       Impact factor: 10.121

7.  Long versus standard initial steroid therapy for children with the nephrotic syndromeA report from the Southwest Pediatric Nephrology Study Group.

Authors:  Marc B Lande; Christina Gullion; Ronald J Hogg; Bernard Gauthier; Binod Shah; Mary B Leonard; Melvin Bonilla-Felix; Martin Nash; Shane Roy; C Frederic Strife; Gerald Arbus
Journal:  Pediatr Nephrol       Date:  2003-03-21       Impact factor: 3.714

Review 8.  The management of idiopathic nephrotic syndrome in children.

Authors:  Elisabeth Hodson
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomised controlled trials.

Authors:  E M Hodson; J F Knight; N S Willis; J C Craig
Journal:  Arch Dis Child       Date:  2000-07       Impact factor: 3.791

10.  Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome.

Authors:  Koichi Nakanishi; Kazumoto Iijima; Kenji Ishikura; Hiroshi Hataya; Hitoshi Nakazato; Satoshi Sasaki; Masataka Honda; Norishige Yoshikawa
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-31       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.